News
Gen Z grads are slamming degrees as worthless—but Fortune 500 boss, Doina Ionescu, says her MBA was the best investment ...
There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...
Two new vaccine advisers tapped by Health and Human Services Secretary Robert F. Kennedy Jr. have served as paid expert ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
Explore more
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results